Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.

Abstract: Provided herein is a vaccine that combines a vaccine facilitator and a DNA construct encoding an antigen to elicit antigen-specific antibody responses, wherein the vaccine facilitator is a Na/K pump inhibitor. Cellular entry of the DNA is accelerated as compared to other vaccines that do not contain the vaccine facilitator.

Abstract: Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.

Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.

Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment.

Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

Abstract: Provided herein are amphiphilic polymers compositions for making aqueous formulations. In one aspect, a solution composition for delivery and release of active ingredients comprises a block co-polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA or PLA-PCL-PEG-PCL-PLA or PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL. The block co-polymers are biodegradable, stable and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents. In some embodiments, the block co-polymers enable sustained and/or continuous release of various active agents. In certain embodiments, the block co-polymers can be used to make an artificial tear preparation, a lubricant for joints or wound cover or adhesive.

Abstract: Provided herein are compositions with enhanced sweetness or reduced caloric content per weight when compared to the sweetener carbohydrate or sweetener polyol component thereof, and methods for the preparation thereof.

Abstract: A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Abstract: There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-?-pyranose and comprising at least one -(1-3)- link between adjacent 4,6-dideoxy-4-acylamido-?-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom, the oligosaccharide being covalently linked to a non-saccharide molecule or to a surface.

Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

Abstract: Described herein are methods, systems, and devices for identifying agents and genetic pathways that modulate the effects of traumatic brain injury (TBI) in invertebrate model systems having a brain, e.g., Drosophila or C. elegans.

Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.

Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.

Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.

Abstract: Provided is a decontamination apparatus for decontaminating an enclosed room. The decontamination apparatus includes a source including a UVC bulb and a reflective shield arranged adjacent to the UVC bulb and configured to reflect UVC light emitted by the UVC bulb toward a region of the enclosed room to be decontaminated. A mounting system that is adjustable secures the source at a desired location within the enclosed room. A controller is operatively-connected to the source to terminate operation of the UVC bulb in response to a determination that an occupant is present within the enclosed room.

Abstract: A sample preparation container, preferably for use in sterility testing, comprising a housing (1) having a housing wall (2) defining an inside space (3), a support on which a membrane filter is placed or is to be placed so as to get in contact with a sampling fluid to be introduced into the inside space (3), and at least one inlet opening (4) to the inside space (3) and at least one outlet opening from the inside space (3). A sampling port (5) is provided for allowing access from the outside to the inside space (3), wherein said sampling port (5) is closed by a septum (6) and the septum (6) is separated from the inside space (3) by a barrier wall (7) which is preferably piercable or breakable on application of an external force, preferably applied through a sampling instrument like a needle (8).

Abstract: A deodorizer includes: a body case having an inlet and an outlet opening outward and having an air duct that provides communication between the inlet and the outlet; a blowing fan included in the body case, for introducing indoor air into the air duct extending from the inlet to the outlet; deodorizing means provided in a middle of the air duct, through which the introduced air can pass; heating means placed to face at least a partial region of the deodorizing means, for heating the deodorizing means at 200° C. or less; and a controller for controlling operations of the blowing fan and the heating means. The deodorizing means includes, on a carrier, an adsorbent that does not oxidatively decompose an adsorbed material, a catalyst component that oxidatively decomposes the adsorbed material, and a rate of conversion of alcohol into acetic acid by the catalyst component is 15% or less on average across the entire deodorizing means.

Abstract: A wax warmer assembly includes a housing having an outermost edge defining an opening. The housing further includes an annular ridge below the outermost edge. The wax warmer assembly further includes a dish with a peripheral edge, a heater affixed to the dish, and a USB power cord in electrical communication with the heater. Further, the dish is disposed in the opening of the housing and the peripheral edge of the dish engages with the annular ridge of the housing.

Abstract: Provided is a compact ion generator. A control substrate (30) and an ion generating section (41) are provided concentrically around a motor (31) without overlapping each other, which motor (31) is configured to cause a fan (33) to rotate. The fan (33) is configured to send, more outwards than a radial direction, air sucked in from a side of a first direction which is along a rotational axis direction. A fan cover (50) has (i) a first air flow path (52) configured to guide, in the radial direction, the air sent by the fan (33) and (ii) a second air flow path (53) configured to cause the air, which has been guided by the first air flow path (52) to flow in the radial direction, to be sent towards the side of the first direction. The ion generating section (41) constitutes a part of a wall of the first air flow path (52).

Abstract: An identification device that combines an antimicrobial coating with a printable substrate. For example, the invention includes a wristband with a face stock supporting indicia which are applied on (such as through thermal transfer printing) or through (such as through direct thermal printing) an antimicrobial layer. The antimicrobial layer is preferably a coating or varnish that is applied as the outermost layer and can bind with thermal transfer printing ink or supports pass through of direct thermal printing on a chemically receptive sublayer. The antimicrobial varnish includes varnish compounds and antimicrobial compounds such as a silver zeolite ion that is configured to react to moisture with a controlled release of microbial disinfectant. Preferably, the wristband is a hospital wristband bearing on-site printed identification indicia for a patient.

Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized dextran containing pendant aldehyde groups with a multi-arm polyethylene glycol amine is described. The hydrogel exhibits little to no swell upon exposure to physiological conditions. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a low swell hydrogel to inhibit complications, such as fibrosis, including scar formation or surgical adhesions.

Abstract: A tissue dressing material for being applied in contact with a tissue of a patient. The tissue dressing material's main component is deacetylated native chitosan. Moreover, a liquid tissue dressing material for being applied in contact with a tissue of a patient, the tissue dressing material being an aqueous mixture. The main component of the constituent(s) of the mixture other than water is deacetylated native chitosan.

Abstract: A preparation at least useful as a bone implant is provided, which contains a solid component including a lithium compound and a calcium compound. The preparation shows an anti-bacterial ability in comparison with a preparation contains the calcium compound but free of the lithium compound.

Abstract: A process of preparing a biodegradable single-phase cohesive hydrogel composition includes preparing 2 to 5 hydrogels that are independently crosslinked so that each hydrogel has a degree of crosslinking in a range from 0.02 to 0.4, and mixing the 2 to 5 hydrogels to obtain a homogenous mixture of 2 to 5 intertwined hydrogels that interpenetrate each other to form a single phase without covalent bonding between the hydrogels, wherein each hydrogel is prepared by a process that comprises independently crosslinking a polymer and the total polymer concentration of the composition is in a range from 5 to 50 mg/g.

Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure.

Abstract: Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

Abstract: Provided are synthetic bone graft substitutes that include bioactive glass and a carrier. Synthetic bone graft substitutes may include bioactive glass, glycerol and polyethylene glycol. Also provided are bone graft substitutes that include collagen and bioactive glass particles. Example bone graft substitutes may include collagen and bioactive glass particles. Other example embodiments may include Type I Bovine Collagen, an angiogenic agent, such as hyaluronic acid, and bioactive glass. Further provided are methods that include administering the present bone graft substitutes to a mammal, e.g., by surgical insertion of the bone graft substitute into the mammal, either alone or in conjunction with one or more implant devices. Further provided are kits that include the present bone grafts.

Abstract: Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease.

Abstract: The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.

Abstract: In one aspect, the invention provides an implantable device comprising a uniform mixture of components including degradable polymer, inorganic bone particulate either natural or synthetic, a drug, and a soluble microporagen. In some embodiments, the uniform mixture further includes a soluble polymer macroporagen. In some embodiments, the uniform mixture is coated with an immobilized outer porous layer comprising or consisting of synthetic or natural inorganic bone granules. In further aspects, the invention provides an implantable device comprising a composite core of degradable polymer, bone, and a drug, and a coating comprising or consisting of microporous bone overlayer covering the degradable composite core.

Abstract: An integrated system for assessing wound exudates from the wound of a patient is described. The system may contain functionality to detect, process and report various wound parameters. The system also may make treatment determinations based on these findings. The system may detect one or more physiological values of the wound exudates from the wound of the patient. The system may means for comparing the one or more detected physiological values to predetermined physiological values in order to obtain a comparison result in real time. The system may include a processor 15 which provides an electronic signal based on a comparison result in which the electronic signal may correspond to guidelines for treating the wound 13. The system may be integrated with other wound treatment devices, such as negative pressure wound therapy devices (NPWT) 9.

Abstract: Exemplary systems for small volume collection for a breastpump system are provided. The systems allow breast milk to flow directly from the breastshield to the collection container without leaving the control volume. A valve is present outside of the milk flow path that does not contact breast milk prior to the milk reaching a collection vessel.

Abstract: The present disclosure illustrates a sensor-controlled nasal aspirator including a distance sensing unit, a micro processing unit and an air pump. The distance sensing unit is configured to sense a distance between a target object and the distance sensing unit. The micro processing unit is configured to store a preset distance, and receive and process the distance transmitted from the distance sensing unit, and transmit an action command signal when the distance is not higher than the preset distance. The air pump is configured to receive the action command signal and performs a target action according to the action command signal.

Abstract: The illustrative embodiments described herein are directed to apparatuses, systems, and methods for applying reduced pressure to subcutaneous tissue site. In one illustrative embodiment, the apparatus includes a sleeve adapted for placement at a subcutaneous tissue site. The sleeve is further adapted to receive a manifold. The sleeve may also have an opening operable to transfer reduced pressure from the manifold to the subcutaneous tissue site. In one embodiment, the apparatus may also include a manifold that is insertable into the sleeve. The manifold may include at least one aperture, and may be operable to deliver reduced pressure to the subcutaneous tissue site via at least one aperture.

Abstract: A wound treatment appliance is provided for treating all or a portion of a wound. In some embodiments, the appliance includes an impermeable flexible overlay for applying a reduced pressure to the covered portion of the wound. The wound treatment appliance may also include a vacuum system to supply reduced pressure to the wound in the area under the flexible overlay, a wound packing means to prevent overgrowth of the wound or to encourage growth of the wound tissue into an absorbable matrix including the wound packing means, a suction drain, a collection chamber to collect and store exudate from the wound, and/or a suction bulb which may be used to provide a source of reduced pressure to an impermeable overlay that covers all or a portion of the wound. Finally, methods are provided for using various embodiments of the wound treatment appliance.

Abstract: The various embodiments disclosed relate to straps that attach to manual breast pumps to allow the user to pump breast milk with leg power rather than by hand. One of two straps is wrapped around each of a user's thighs. Both straps have fasteners to enable the straps to be securely wrapped around the thigh. The straps are then connected to a manual breast pump. The breast pump can be connected to the manual breast pump by adding fasteners to the breast pump, or by threading the breast pump hoses through the pump connector. After the breast pump has been connected to the pump connectors, the user places the breast cup on their breasts. The user then begins pumping the manual pump by repeatedly moving their legs in an outward and inward motion.

Abstract: Cannula assemblies and methods of manufacturing cannula assemblies are provided. The cannula assembly includes a cannula and a pigtail extension coupled to the cannula. The pigtail extension includes a proximal section having a first stiffness and a distal section having a second stiffness, the first stiffness greater than the second stiffness. The proximal section of the pigtail extension is positioned between the cannula and at least a portion of the distal section.

Abstract: The disclosure relates to a pump for implantation into a vessel or a heart, with the pump being introduced in a first state into the vessel or heart in order then be functionally changed over to a second state in the vessel or in the heart, having a drive part and a delivery part, where the drive part is not functional in the first state and becomes functional as a result of the changeover to the second state, wherein the drive part has an electric motor, where the electric motor is embodied as a wet rotor, and where, in the first state, the rotor of the electric motor and the stator of the electric motor are arranged so as to be separate from one another, and where the rotor of the electric motor is moved into the stator of the electric motor in the second state, where the rotor can drive the delivery part in the second state.

Abstract: Methods, systems, and devices for an updatable blood pump are disclosed herein. The blood pump can be part of a mechanical circulatory support system that can include a system controller and the blood pump. The blood pump can include a rotary motor and a control unit that can communicate with the system controller. The system controller can initiate the update process and can provide the update to the blood pump. Upon initiation of the update process, the control unit can stop the rotary motor. While the rotary motor is stopped, the blood pump can be updated. At the completion of the update, the rotary pump can be restarted.

Abstract: A dialysis machine comprising: a microphone; an alert module for producing an audible alert related to an operating condition of the dialysis machine; and a processing module configured for: receiving, from the microphone, information related to measured noise; determining, based on the information related to measured noise, an audible alert that will not be masked by the measured noise when the audible alert is produced by the alert module; and providing, to the alert module, instructions for producing the audible alert.

Abstract: A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

Abstract: A membrane separation device is disclosed along with systems and methods employing the device in blood processing procedures. In one embodiment, a spinning membrane separator is provided in which at least two zones or regions are created in the gap between the spinning membrane and the shell, such that mixing of the fluid between the two regions is inhibited by a radial rib or ridge associated with the spinning membrane that decreases the gap between the spinning membrane and the shell to define two fluid regions, the ridge isolating the fluid in the two regions to minimize mixing between the two. Automated systems and methods are disclosed for separating a unit of previously-collected whole blood into selected blood components, such as concentrated red cells and plasma, for collecting red cells and plasma directly from a donor in a single pass, and for cell washing. Data management systems and methods and priming methods are also disclosed.

Abstract: A catheter for vascular insertion, including a catheter body defining a first lumen and a second lumen, and including a distal region. The distal region includes an atraumatic nose portion defining a first distal opening in fluid communication with the first lumen, and a second distal opening in fluid communication with the second lumen. The distal region also includes a first lateral opening defined by the catheter body and in fluid communication with the first lumen, and a second lateral opening defined by the catheter body and in fluid communication with the second lumen. One or both of the first and second lateral openings may be defined by an angle cross-cut through an outer perimeter of the catheter body.

Abstract: Systems and methods are provided for separating blood into two or more separated blood components. The system includes a blood separation chamber with a single stage having five ports connected thereto. The five ports include a blood inlet port, a red blood cell outlet port, a platelet-rich plasma outlet port, a platelet-poor plasma outlet port, and a buffy coat outlet port. In the single stage, blood may be separated into a variety of components, such as red blood cells and platelet-rich plasma or red blood cells, platelet-poor plasma, and buffy coat. Depending on the components into which the blood is to be separated, flow out of one or more of the outlet ports may be prevented.